PlexusDx's Precision Peptide Genetic Test identifies variations in GLP1R, GIPR, FTO, and MC4Rgenes that influence satiety signaling and metabolic risk
Nearly 1 in 5 Americans have used GLP-1s While these medications have hit the market relatively recently, a significant portion of the adult population in the United States reports that they have already tried them
Previous treatments: Information on any other weight loss or diabetes treatments youve previously tried, including medications, diet, and exercise programs
Similarly, another study found that overweight or obese adults who completed a 20-week run-in period and continued their treatment with semaglutide experienced ongoing weight loss as compared to those who took placebo [3]
PY: Methodology, Software, Writing original draft
Anekwe highlights that "some research shows GLP-1s may slow cognitive decline and have a role in neuroprotection." Addiction treatment